Search research articles
Contact Us
Filters
Showing results (311-320 of 353) with videos related to
Page
of 36
Sort By:
Clinical Pharmacology and Therapeutics
|
February 16, 2018
Model-Informed Drug Development for Ixazomib, an Oral Proteasome Inhibitor
Neeraj Gupta, Michael J Hanley, Paul M Diderichsen, et al.
British Journal of Haematology
|
May 20, 2016
A pharmacokinetics and safety phase 1/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or end-stage renal disease requiring haemodialysis
Neeraj Gupta, Michael J Hanley, R Donald Harvey, et al.
Clinical Pharmacology in Drug Development
|
November 16, 2022
Effect of Pevonedistat, an Investigational NEDD8-Activating Enzyme Inhibitor, on the QTc Interval in Patients With Advanced Solid Tumors
Xiaofei Zhou, Debra L Richardson, Afshin Dowlati, et al.
Microbiology Spectrum
|
February 27, 2026
Diagnostic disruption during a blood culture bottle shortage: clinical and laboratory adaptation strategies
Haripriya Bansal, Aditi Gupta, Kuntal Kumar Sinha, et al.
Blood
|
June 7, 2014
Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma
Shaji K Kumar, William I Bensinger, Todd M Zimmerman, et al.
Journal of Clinical Pharmacology
|
April 19, 2017
Population Pharmacokinetic Analysis of Bortezomib in Pediatric Leukemia Patients: Model-Based Support for Body Surface Area-Based Dosing Over the 2- to 16-Year Age Range
Michael J Hanley, Diane R Mould, Timothy J Taylor, et al.
The Journal of Asthma : Official Journal of the Association for the Care of Asthma
|
March 15, 2024
Efficacy and safety of Once-Daily Vilanterol/Fluticasone furoate MDI in persistent asthma: Phase 3 OD-INHALE Study
Avdhesh Kumar, Manish Kumar Jain, Vijaykumar Bhagwan Barge, et al.
The Lancet. Global Health
|
March 1, 2025
Multidrug-resistant sepsis in special newborn care units in five district hospitals in India: a prospective cohort study
Kajal Jain, Vivek Kumar, Nishad Plakkal, et al.
Cureus
|
September 15, 2022
Mortality and Its Predictors in COVID-19 Patients With Pre-existing Interstitial Lung Disease
Naveen Dutt, Saumya Shishir, Nishant K Chauhan, et al.
Blood
|
June 13, 2014
Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients
Paul G Richardson, Rachid Baz, Michael Wang, et al.
Page
of 36
Search research articles
Search
Showing results (311-320 of 353) with videos related to
Sort By:
Page
of 36
Clinical Pharmacology and Therapeutics
|
February 16, 2018
Model-Informed Drug Development for Ixazomib, an Oral Proteasome Inhibitor
Neeraj Gupta, Michael J Hanley, Paul M Diderichsen, et al.
British Journal of Haematology
|
May 20, 2016
A pharmacokinetics and safety phase 1/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or end-stage renal disease requiring haemodialysis
Neeraj Gupta, Michael J Hanley, R Donald Harvey, et al.
Clinical Pharmacology in Drug Development
|
November 16, 2022
Effect of Pevonedistat, an Investigational NEDD8-Activating Enzyme Inhibitor, on the QTc Interval in Patients With Advanced Solid Tumors
Xiaofei Zhou, Debra L Richardson, Afshin Dowlati, et al.
Microbiology Spectrum
|
February 27, 2026
Diagnostic disruption during a blood culture bottle shortage: clinical and laboratory adaptation strategies
Haripriya Bansal, Aditi Gupta, Kuntal Kumar Sinha, et al.
Blood
|
June 7, 2014
Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma
Shaji K Kumar, William I Bensinger, Todd M Zimmerman, et al.
Journal of Clinical Pharmacology
|
April 19, 2017
Population Pharmacokinetic Analysis of Bortezomib in Pediatric Leukemia Patients: Model-Based Support for Body Surface Area-Based Dosing Over the 2- to 16-Year Age Range
Michael J Hanley, Diane R Mould, Timothy J Taylor, et al.
The Journal of Asthma : Official Journal of the Association for the Care of Asthma
|
March 15, 2024
Efficacy and safety of Once-Daily Vilanterol/Fluticasone furoate MDI in persistent asthma: Phase 3 OD-INHALE Study
Avdhesh Kumar, Manish Kumar Jain, Vijaykumar Bhagwan Barge, et al.
The Lancet. Global Health
|
March 1, 2025
Multidrug-resistant sepsis in special newborn care units in five district hospitals in India: a prospective cohort study
Kajal Jain, Vivek Kumar, Nishad Plakkal, et al.
Cureus
|
September 15, 2022
Mortality and Its Predictors in COVID-19 Patients With Pre-existing Interstitial Lung Disease
Naveen Dutt, Saumya Shishir, Nishant K Chauhan, et al.
Blood
|
June 13, 2014
Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients
Paul G Richardson, Rachid Baz, Michael Wang, et al.
Page
of 36